Coultreon Biopharma, formerly Onco3R Therapeutics, raised a $125 million Series A to advance its oral SIK3 inhibitor COL-5671 through clinical development. The seed for the program traces back to Galapagos asset selection, and Coultreon said Phase 1 plans include transitioning into Phase 2 next year for autoimmune diseases including psoriasis and ulcerative colitis. In immunology financing, separate reporting noted that investor participation included Sofinnova as the lead and Forbion and Novo Holdings as co-leads. Coultreon said the program targets SIK3 to shift cytokine production toward immunoregulatory signaling. The diagnostics segment also saw capital flow through CareDx’s announced acquisition of Naveris for up to $260 million, tying financing to revenue milestones and reimbursement for its HPV liquid biopsy test. Overall, funding continues to reward differentiated mechanism-based platforms with credible clinical and regulatory pathways.